Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Collaboration by Quarter
CRISPR Collaboration — Total collaboration expenses recognized (historical, $M) ($M)
Vertex Pharmaceuticals CRISPR Collaboration: $95.2M in Q4 2022, up 92.7% from a year earlier. That is the highest of the 8 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2022 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2023-02-10) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Collaboration — Total collaboration expenses recognized (historical, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Dec 31, 2022 | 95.2 | +92.7% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2022 | Sep 30, 2022 | 59 | +67.6% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 50.9 | +85.1% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 46 | +130.0% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 49.4 | – | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2021 | Sep 30, 2021 | 35.2 | – | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 27.5 | – | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 20 | – | Form 10-Q (filed 2022-05-06) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Collaboration ($M), quarterly Q1 2021–Q4 2022 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-tot-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.